[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-279438-105":3,"detail-sidebar-cat-1-en-105":81,"doc-detail-279438-en":126},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","itvisma-navigating-the-insurance-coverage-approval-process-a-step-by-step-guide-for-health-care-professionals-and-access-coordinators","ITVISMA - Navigating the Insurance Coverage Approval Process - A Step-by-Step Guide for Health Care Professionals and Access Coordinators","","A step-by-step guide for health care professionals and access coordinators to navigate insurance coverage approval for ITVISMA (onasemnogene abeparvovec-brve) for adult and pediatric patients aged 2 years and older with genetically confirmed spinal muscular atrophy (SMA). It outlines key steps, required prior authorizations, exceptions, appeals, and approval/treatment considerations, along with a structured overview of required testing (including anti-AAV9 antibodies, liver function and laboratory assessments) before administration. The guide also includes important safety information with emphasis on boxed warning for serious liver injury and monitoring.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/template/","Template",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/template/forms/","Forms",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/template/itvisma-navigating-the-insurance-coverage-approval-process-a-step-by-step-guide-for-health-care-professionals-and-access-coordinators/279438/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/itvisma-navigating-the-insurance-coverage-approval-process-a-step-by-step-guide-for-health-care-professionals-and-access-coordinators/279438.png","ImageObject",442,249,{"name":42,"@type":43},"Anda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-16",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What patient and documentation criteria should be confirmed before submitting an insurance prior authorization for ITVISMA?","Question",{"text":63,"@type":64},"Determine the specific coverage criteria of the patient’s health plan, including out-of-pocket costs, required acquisition or site-of-care methods, and coding/billing information. Document the patient’s clinical history in the PA request form, as payors may require plan- or circumstance-specific documentation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What testing is typically required before patients receive ITVISMA?",{"text":68,"@type":64},"Genetic confirmation of SMA diagnosis (or historical documentation), baseline anti-AAV9 antibody testing, and laboratory assessments for liver function (including ALT/AST and other listed labs). Additional assessments include creatinine, complete blood count, and confirmation of pregnancy status for females of reproductive potential.",{"name":70,"@type":61,"acceptedAnswer":71},"What boxed safety warning is highlighted for ITVISMA?",{"text":72,"@type":64},"ITVISMA carries a boxed warning for serious liver injury. Acute serious liver injury and hepatotoxicity may occur, requiring pre- and post-injection systemic corticosteroid administration, liver function assessment prior to dosing, and continued monitoring for at least 3 months.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},279438,1790008306,{"code":4,"msg":82,"data":83},"success",[84,88,93,98,103,108,112,117,122],{"id":55,"doc_module":22,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Presentations",90,"presentations",{"id":89,"doc_module":22,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},12,"Resumes",80,"resumes",{"id":94,"doc_module":22,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},14,"Invoices",70,"invoices",{"id":99,"doc_module":22,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},15,"Posters",60,"posters",{"id":104,"doc_module":22,"doc_module_name":25,"category_name":105,"show_sort_weight":106,"slug":107},16,"Social Media",50,"social-media",{"id":109,"doc_module":22,"doc_module_name":25,"category_name":29,"show_sort_weight":110,"slug":111},17,40,"forms",{"id":113,"doc_module":22,"doc_module_name":25,"category_name":114,"show_sort_weight":115,"slug":116},18,"Letters",30,"letters",{"id":118,"doc_module":22,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},21,"Paper Templates",5,"papers-templates",{"id":123,"doc_module":22,"doc_module_name":25,"category_name":124,"show_sort_weight":4,"slug":125},158,"General","general-158",{"code":4,"msg":82,"data":127},{"doc_id":79,"user_id":128,"nickname":42,"user_avatar":129,"doc_module":22,"category_id":109,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":99,"language":135,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":136,"faqs":137,"seo_title":138,"seo_description":12,"update_tm":139,"read_time":120},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Key Steps  \nRequired Testing  \nPrior Authorizations  \nExceptions  \nAppeals  \nApproval and Treatment  \nResources  \nImportant Safety Information  \nPrior Authorizationsand Appeals Guide  \nA Step-by-Step Guide for Health Care Professionalsand Access Coordinators to Help Navigate Coverage for Adult and Pediatric Patients Aged 2 Years and Older With Spinal Muscular Atrophy  \nINDICATION  \nITVISMA is indicated for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in survival motor neuron 1 (SMN1) gene.  \nIMPORTANT SAFETY INFORMATION  \nBOXED WARNING: Serious Liver Injury  \nAcute serious liver injury can occur with ITVISMA. Hepatotoxicity, with elevated alanine transaminase (ALT) and/or aspartate transaminase (AST) levels, has occurred with ITVISMA. Patients with preexisting hepatic impairment or acute hepatic viral infection may be at higher risk of liver injury. To mitigate potential aminotransferase elevations, administer systemic corticosteroid before and after ITVISMA injection. Prior to ITVISMA injection, assess liver function by clinical examination and laboratory testing. Continue to monitor liver function for at least 3 months after ITVISMA administration, and at other times as clinically indicated. In case hepatic injury is suspected, further testing is recommended. Promptly consult with a gastroenterologist or hepatologist, as necessary.  \nPlease see Indication and Important Safety Information on page 15 and click here for Full Prescribing Information, including Boxed WARNING.  \n1  \nKey Steps in the Insurance Coverage Approval Process  \nNavigating the insurance approval process for  \nITVISMA® (onasemnogene abeparvovec-brve)  \nOnce the decision to prescribe ITVISMA is made, determine the specific coverage criteria for your patient’s health plan, including any patient out-of-pocket costs, methods of acquisition or sites of care required by the health plan, and coding and billing information.  \n• Coverage requirements for ITVISMA may vary from patient to patient based on their individual health plan and circumstances  \n• It is important to review and understand the health plan’s eligibility requirements specific to ITVISMA  \nInitial PA or Medical Exception Request  \nSome patients will be approved without a denial  \nFor assistance throughout the insurance approval process for ITVISMA  \nCONTACT your RAAD, your access and reimbursement specialist at Novartis  \nCALL Novartis Patient SupportTMat 1-855-441-4363, Monday through Friday (8 am to 8pm ET)  \nPA, prior authorization; RAAD, Regional Account Associate Director.  \nPlease see Indication and Important Safety Information on page 15 and click here for Full Prescribing Information,  \nincluding Boxed WARNING. 2  \nRequired Testing for  \nITVISMA® (onasemnogene abeparvovec-brve)  \nBefore receiving ITVISMA, patients must have a genetically confirmed SMA diagnosis, baseline testing for the presence of anti-AAV9 antibodies, and lab assessments to ensure eligibility and safe administration 1 These tests can be ordered by the referring or treating physician. As a reminder, some patients may have already had genetic confirmation tests completed.  \nTests typically required for ITVISMA  \n Genetic confirmation of SMA diagnosis or historical documentation of prior test  \n Baseline testing for the presence of anti–AAV9 antibodies1  \n Lab assessments for liver function (clinical examination, AST, ALT, albumin, prothrombin time, PTT, INR, and total bilirubin)1  \n Creatinine and complete blood count (including hemoglobin and platelet count)1  \n The pregnancy status of females of reproductive potential should be verified prior to treatment with ITVISMA1  \nNovartis Laboratory Testing Program  \n• Novartis partners with Athena® Diagnostics and CTL to sponsor the Novartis Laboratory Testing Program to provide test kits and cover the cost of diagnostic tests for SMA genetic testing and anti–AAV9 antibody tests*  \n• Athena Diagnos","cbCaid1aEOkSaZ3f","https://ap.wps.com/l/cbCaid1aEOkSaZ3f","pdf",1450653,"English","# Key Steps in the Insurance Coverage Approval Process\n## Initial PA or Medical Exception Request\n# Required Testing for ITVISMA\n## Novartis Laboratory Testing Program\n# Preparing the Initial Prior Authorization Submission\n## Patient documentation for payor criteria\n# Important Safety Information\n## Boxed Warning: Serious Liver Injury","[{\"question\":\"What patient and documentation criteria should be confirmed before submitting an insurance prior authorization for ITVISMA?\",\"answer\":\"Determine the specific coverage criteria of the patient’s health plan, including out-of-pocket costs, required acquisition or site-of-care methods, and coding/billing information. Document the patient’s clinical history in the PA request form, as payors may require plan- or circumstance-specific documentation.\"},{\"question\":\"What testing is typically required before patients receive ITVISMA?\",\"answer\":\"Genetic confirmation of SMA diagnosis (or historical documentation), baseline anti-AAV9 antibody testing, and laboratory assessments for liver function (including ALT/AST and other listed labs). Additional assessments include creatinine, complete blood count, and confirmation of pregnancy status for females of reproductive potential.\"},{\"question\":\"What boxed safety warning is highlighted for ITVISMA?\",\"answer\":\"ITVISMA carries a boxed warning for serious liver injury. Acute serious liver injury and hepatotoxicity may occur, requiring pre- and post-injection systemic corticosteroid administration, liver function assessment prior to dosing, and continued monitoring for at least 3 months.\"}]","ITVISMA - Navigating the Insurance Coverage Approval Process - A Step-by-Step Guide for Health Care Professionals and Access Coordinators | PDF",1789520766]